OrbiMed Royalty Opportunities Fund is a private equity general partner firm with offices in China, India, Israel and United States.
OrbiMed-backed Unilife, which makes injections and insulin patch pumps, is reviewing strategic alternatives, including a sale.
Healthcare-focused OrbiMed issued $60m in debt to Unilife, a US-based company that designs and manufactures injectable drug delivery systems
Iroko Pharmaceuticals, a global specialty pharmaceutical company focused on analgesia, has secured a $75m debt facility from OrbiMed.
Read more news concerning OrbiMed Royalty Opportunities Fund
This firm also pursues other investment strategies:
Registration is fast, free and easy
Already a member?